Dr. Wang on the Utility of CAR T-Cell Therapy in Relapsed/Refractory MCL


Michael Wang, MD, discusses the utility of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the utility of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma (MCL).

A fraction of MCL is particularly aggressive, says Wang; the disease can progress through multiple lines of chemotherapy and targeted therapies.

CAR T-cell therapy offers an alternate way to treat MCL, explains Wang. T cells are obtained from the patients and are then examined in the lab. A gene transfer is performed, the T cells are put into a product, and then they are put back into the patient. The T cells identify the lymphoma cells, bind to them, and cure them, explains Wang.

Many studies have demonstrated that his approach is very effective, even those done in more aggressive cancers such as acute lymphoblastic leukemia and large cell lymphoma, says Wang.

One such product that is showing promise in this space is KTE-X19. In February 2020, a biologics license application for the agent was granted a priority review designation by the FDA for the treatment of patients with relapsed/refractory MCL based on positive findings from the phase 2 ZUMA-2 trial. Results showed that a single infusion of KTE-X19 elicited a 93% objective response rate and a 67% complete response rate in this patient population.

Related Videos
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
© 2024 MJH Life Sciences

All rights reserved.